Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia

Immunology

Volumn 139, Issue 4, 2013, Pages 513-522

  Yang, Wen ^a   Song, Yan ^a   Lu, Yun Long ^a   Sun, Jun Zhong ^a   Wang, Hong Wei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cervical intraepithelial neoplasia; Cytokines; Human papillomavirus; Programmed death 1; Programmed death 1 ligand

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOLOGY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN TISSUE; MORPHOLOGY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; UPREGULATION; UTERINE CERVIX CARCINOMA IN SITU;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOKINES; HUMAN PAPILLOMAVIRUS; PROGRAMMED DEATH-1; PROGRAMMED DEATH-1 LIGAND;

ADULT; ANTIGENS, CD274; ANTIGENS, CD80; ANTIGENS, CD86; BIOPSY; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXUDATES AND TRANSUDATES; FEMALE; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84879804595     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12101     Document Type: Article

References (40)

1. Insinga RP, Perez G, Wheeler CM et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011; 20:287-96.
2. Mougin C, Mo L, Dalstein V. Natural history of papillomavirus infections. Rev Prat 2006; 56:1883-9.
3. Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res 2007; 33:103-13.
4. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006; 16:83-97.
5. Passmore JA, Milner M, Denny L et al. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia. Immunology 2006; 119:507-14.
6. + T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 2007; 13:2479-87.
7. Chen XZ, Mao XH, Zhu KJ, Jin N, Ye J, Cen JP, Zhou Q, Cheng H. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells. Arch Dermatol Res 2010; 302:57-65.
8. Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol 2001; 166:5917-24.
9. Chiriva-Internati M, Liu Y, Salati E et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol 2002; 32:30-8.
10. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001; 8:209-20.
11. Guzmán-Olea E, Bermúdez-Morales VH, Peralta-Zaragoza O, Torres-Poveda K, Madrid-Marina V. Molecular mechanism and potential targets for blocking HPV-induced lesion development. J Oncol 2012; 2012:278312.
12. Nguyen HH, Broker TR, Chow LT et al. Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol 2005; 96:452-61.
13. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111-22.
14. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206:3015-29.
15. Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol 2011; 2011:451694.
16. Watanabe T, Bertoletti A, Tanoto TA. PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat 2010; 17:453-8.
17. Syrjänen S, Naud P, Sarian L et al. Up-regulation of 14-3-3sigma (Stratifin) is associated with High-Grade CIN and high-risk human papillomavirus (HPV) at baseline but does not predict outcomes of HR-HPV infections or incident CIN in the LAMS study. Am J Clin Pathol 2010; 133:232-40.
18. + mononuclear cells from the human cervix. J Immunol Methods 2001; 258:37-46.
19. Castle PE, Giuliano AR. Genital tract infections, cervical inflammation, and antioxidant nutrients - assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 2003; 31:29-34.
20. Kojima S, Kawana K, Fujii T et al. Characterization of gut-derived intraepithelial lymphocyte (IEL) residing in human papillomavirus (HPV)-infected intraepithelial neoplastic lesions. Am J Reprod Immunol 2011; 66:435-43.
21. Trimble CL, Clark RA, Thoburn C et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 2010; 185:7107-14.
22. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515-48.
23. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-7.
24. Zhang Z, Jin B, Zhang JY et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol 2009; 50:1163-73.
25. Kojima S, Kawana K, Tomio K et al. The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN. Am J Reprod Immunol 2013; 69:134-41.
26. + T-cell responses by soluble PD-1. J Immunother 2011; 34:297-306.
27. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27:195-201.
28. Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, Dalpke AH, Heeg K. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 2011; 41:413-24.
29. Peña-Cruz V, McDonough SM, Diaz-Griffero F, Crum CP, Carrasco RD, Freeman GJ. PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity. J Invest Dermatol 2010; 130:2222-30.
30. Shen T, Chen X, Chen Y, Xu Q, Lu F, Liu S. Increased PD-L1 expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection. J Med Virol 2010; 82:1152-9.
31. Bais AG, Beckmann I, Ewing PC, Eijkemans MJ, Meijer CJ, Snijders PJ, Helmerhorst TJ. Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls. Mediators Inflamm 2007; 2007:24147.
32. Scott ME, Ma Y, Kuzmich L, Moscicki AB. Diminished IFN-γ and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer 2009; 124:1379-83.
33. Bermudez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM, Burguete A, Madrid-Marina V. Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest 2008; 26:1037-43.
34. Bais AG, Beckmann I, Lindemans J, Ewing PC, Meijer CJ, Snijders PJ, Helmerhorst TJ. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 2005; 58:1096-100.
35. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005; 78:1043-51.
36. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34.
37. Said EA, Dupuy FP, Trautmann L et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010; 16:452-9.
38. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54:307-14.
39. Lee SJ, Jang BC, Lee SW et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett 2006; 580:755-62.
40. + T cells and is overcome by IL-2. Eur J Immunol 2002; 32:634-43.